OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 81. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
AI serves up target and inhibitor for lung fibrosis	2471
Vaccine exposes tumours to immune cell attack	1410
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	820
A specific biomarker for insoluble tau	624
Targeting tumour-associated bacteria	600
A new path to targeted protein degradation?	596
Neutralizing Zika virus	579
The improving benefit–risk balance of phase I cancer trials	555
FDA approves a c-MET-targeted ADC for lung cancer	536
Tumour cells get a dendritic cell makeover	505
Glucose-sensitive insulin protects against hypoglycaemia	485
Promoting tissue repair after heart attack	419
mRNA-encoded monoclonal antibody fights CHIKV	389
Hypoimmune iPSCs escape immune detection	383
Lipid nanoparticle ferries therapeutic mRNA to the placenta	382
FDA new drug approvals in Q1 2023	358
Apolipoprotein L2 inhibitor mitigates fibrosis	334
Degrading cell-free DNA to prevent recurrent stroke	333
FDA approves second TTR stabilizer for cardiac amyloidosis	325
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	322
Evolution of innovative drug R&D in China	322
2022 FDA approvals	305
Anti-tau antibody stumbles in phase II Alzheimer trial	303
New antibiotic for urinary tract infections nabs FDA approval	300
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	286

Small-molecule discovery through DNA-encoded libraries	280
Targeting drug-resistant glioblastoma	280
Chemical engineering of CRISPR–Cas systems for therapeutic application	277
Targeting the Hippo pathway in cancer	275
Top companies and drugs by sales in 2021	267
mRNA vaccines for infectious diseases — advances, challenges and opportunities	252
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	243
Increasing the potency of T cell therapies	229
Small molecule improves muscle function in myasthenia gravis	227
Blocking breast cancer metastasis	221
Pushing both sides of the drug pricing aisle	218
Host-directed antiviral blocks SARS-CoV-2 entry	217
TCR-engineered T cells get personal	203
FDA new drug approvals in Q2 2023	191
Inhibiting ASGR1 boosts cholesterol removal	187
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	182
Rewired proteostasis in KRAS inhibitor resistance	178
R&D re-balancing act	174
Screening ultra-large virtual libraries	171
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	170
A call to action for translational sciences in COVID-19 and future pandemics	167
Mimicking the health benefits of exercise	163
Reflections on 10 years of the FDA’s breakthrough therapy designation	162
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	158
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	157
The significance of blockbusters in the pharmaceutical industry	153
FDA approves second BCMA-targeted CAR-T cell therapy	152
Base editors hit the clinic	150
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	147
Amylin takes another shot at the obesity prize	135
Pan-coronavirus vaccine pipeline takes form	127
The emerging role of mass spectrometry-based proteomics in drug discovery	122
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	118
The antibody–drug conjugate landscape	118
Phenotypic drug discovery: recent successes, lessons learned and new directions	113
Antibody–drug conjugates come of age in oncology	113
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	111
Combating antimicrobial resistance in malaria, HIV and tuberculosis	110
Multi-TACs target solid tumours	107
Immunology on the brain	107
Gut metabolite mediates nerve repair	106
Reducing IL-2 toxicity	104
Agonist antibody lowers blood pressure	100
Monkeypox mRNA vaccine protects mice and macaques	98
Neglected tropical diseases go global	97
The malignant melanoma market	95
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	95
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	93
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	93
Anti-IL-11 antibody shows anti-ageing properties	92

GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	90
Ribosome inhibitor combats bacterial drug resistance	88
Designing G-protein-selective allosteric modulators	86
The European Innovation Network as a hub for medicines innovation in Europe	85
Targeting the ECM in melanoma	84
LRRK2-targeted Parkinson disease drug advances into phase III	82
Frameworks for transformational breakthroughs in RNA-based medicines	81
Avidity in antibody effector functions and biotherapeutic drug design	81